Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
1.
Leukemia ; 24(6): 1179-85, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20428208

ABSTRACT

Cancer often originates from a site of persistent inflammation, and the mechanisms turning chronic inflammation into a driving force of carcinogenesis are intensely investigated. Cyclooxygenase-2 (COX-2) is an inducible key modulator of inflammation that carries out the rate-limiting step in prostaglandin synthesis. Aberrant COX-2 expression and prostaglandin E(2) (PGE(2)) production have been implicated in tumorigenesis. In this study we show that COX-2 is ectopically expressed in malignant T-cell lines from patients with cutaneous T-cell lymphoma (CTCL) as well as in situ in lymphocytic cells in 21 out of 22 patients suffering from mycosis fungoides (MF) in plaque or tumor stage. COX-2 is not expressed in lymphocytes of 11 patients with patch-stage MF, whereas sporadic COX-2 staining of stromal cells is observed in the majority of patients. COX-2 expression correlates with a constitutive production of PGE(2) in malignant T cells in vitro. These cells express prostaglandin receptors EP3 and EP4 and the receptor antagonist as well as small interfering RNA (siRNA) directed against COX-2, and specific COX-2 inhibitors strongly reduce their spontaneous proliferation. In conclusion, our data indicate that COX-2 mediated PGE(2) exerts an effect as a tumor growth factor in MF.


Subject(s)
Cyclooxygenase 2/metabolism , Lymphoma, T-Cell, Cutaneous/metabolism , Mycosis Fungoides/metabolism , Prostaglandins E/pharmacology , Skin Neoplasms/metabolism , Blotting, Western , Cell Proliferation , Cyclooxygenase 2/chemistry , Cyclooxygenase 2/genetics , Cyclooxygenase 2 Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Immunoenzyme Techniques , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/pathology , Mycosis Fungoides/drug therapy , Mycosis Fungoides/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Receptors, Prostaglandin E/metabolism , Receptors, Prostaglandin E, EP3 Subtype , Reverse Transcriptase Polymerase Chain Reaction , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Tumor Cells, Cultured
2.
Br J Ophthalmol ; 93(8): 1047-51, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19429588

ABSTRACT

AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region. METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005. Specimens were collected from Danish pathological departments and re-evaluated with a panel of monoclonal antibodies. For all patients with confirmed MCL the complete clinical files were collected and reviewed. RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region. There were 18 male patients and three female patients with an age range from 60 to 90 years (median 75 years). Orbital and adnexal region MCL as first presenting symptom comprised 67% of the patients. Of these, 71% had bilateral involvement. The orbit (71%) and eyelids (64%) were the most commonly affected sites. All but two presented in stage III/IV. Secondary MCL comprised 33% of the patients. Bilateral affection (29%) was less common in this patient group. The median survival was not different between the two presentation groups. Patients receiving anti-CD20 (rituximab)-containing chemotherapy had a significantly better 5-year overall survival (OS) rate (83%) than patients in treatment regimes without rituximab (5-year OS rate, 8%). CONCLUSIONS: Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients presented with stage IV disease and had multiple relapses and short survival time. Treatment with rituximab-containing chemotherapy improved survival significantly compared with combination chemotherapy without rituximab.


Subject(s)
Eye Neoplasms/pathology , Lymphoma, Mantle-Cell/pathology , Aged , Aged, 80 and over , Eye Neoplasms/therapy , Female , Humans , Lymphoma, Mantle-Cell/therapy , Male , Middle Aged , Neoplasm Staging , Orbital Neoplasms/pathology , Orbital Neoplasms/therapy , Prognosis , Survival Analysis , Treatment Outcome
3.
Leukemia ; 22(12): 2230-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18769452

ABSTRACT

Sézary syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma. During disease progression, immunodeficiency develops; however, the underlying molecular and cellular mechanisms are not fully understood. Here, we study the regulatory T cell (Treg) function and the expression of FOXP3 in SS. We demonstrate that malignant T cells in 8 of 15 patients stain positive with an anti-FOXP3 antibody. Western blotting analysis shows expression of two low molecular splice forms of FOXP3, but not of wild-type (wt) FOXP3. The malignant T cells produce interleukin-10 and TGF-beta and suppress the growth of non-malignant T cells. The Treg phenotype and the production of suppressive cytokines are driven by aberrant activation of Jak3 independent of the FOXP3 splice forms. In contrast to wt FOXP3, the low molecular splice forms of FOXP3 have no inhibitory effect on nuclear factor-kappaB (NF-kappaB) activity in reporter assays which is in keeping with a constitutive NF-kappaB activity in the malignant T cells. In conclusion, we show that the malignant T cells express low molecular splice forms of FOXP3 and function as Tregs. Furthermore, we provide evidence that FOXP3 splice forms are functionally different from wt FOXP3 and not involved in the execution of the suppressive function. Thus, this is the first description of FOXP3 splice forms in human disease.


Subject(s)
Forkhead Transcription Factors/genetics , Sezary Syndrome/genetics , Sezary Syndrome/immunology , Skin Neoplasms/genetics , Skin Neoplasms/immunology , T-Lymphocytes, Regulatory/physiology , Adult , Aged , Alternative Splicing , Antigens, CD/metabolism , CTLA-4 Antigen , Cell Line, Tumor , Female , Forkhead Transcription Factors/metabolism , Gene Expression Regulation, Neoplastic , Humans , Immunophenotyping , Interleukin-10/metabolism , Interleukin-2 Receptor alpha Subunit/metabolism , Janus Kinase 3/metabolism , Luciferases/genetics , Male , Middle Aged , NF-kappa B/metabolism , RNA, Small Interfering , STAT5 Transcription Factor/metabolism , Sezary Syndrome/pathology , Skin Neoplasms/pathology , T-Lymphocytes, Regulatory/pathology , Transforming Growth Factor beta/metabolism
4.
Histopathology ; 53(3): 267-77, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18671804

ABSTRACT

AIMS: Aberrant histone acetylation has been associated with malignancy and histone deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials. So far, the malignancy most sensitive to HDAC inhibitors has been cutaneous T-cell lymphoma (CTCL). The reason for this sensitivity is unclear and studies on HDAC expression and histone acetylation in CTCL are lacking. The aim of this study was to address this issue. METHODS AND RESULTS: The immunohistochemical expression of HDAC1, HDAC2, HDAC6, and acetylated H4 was examined in 73 CTCLs and the results related to histological subtypes and overall survival. HDAC1 was most abundantly expressed (P < 0.0001), followed by HDAC2; HDAC6 and H4 acetylation were equally expressed. HDAC2 (P = 0.001) and H4 acetylation (P = 0.03) were significantly more common in aggressive than indolent CTCL subtypes. In contrast, no differences were observed for HDAC1 and HDAC6. In a Cox analysis, elevated HDAC6 was the only parameter showing significant influence on survival (P = 0.04). CONCLUSIONS: High expression of HDAC2 and acetylated H4 is more common in aggressive than indolent CTCL. HDAC6 expression is associated with a favorable outcome independent of the subtype.


Subject(s)
Histone Deacetylases/metabolism , Histones/metabolism , Lymphoma, T-Cell, Cutaneous/diagnosis , Repressor Proteins/metabolism , Skin Neoplasms/diagnosis , Acetylation , Cell Line, Tumor , Enzyme Inhibitors/pharmacology , Histone Deacetylase 1 , Histone Deacetylase 2 , Histone Deacetylase 6 , Histone Deacetylase Inhibitors , Histones/antagonists & inhibitors , Humans , Immunohistochemistry , Lymphoma, T-Cell, Cutaneous/enzymology , Lymphoma, T-Cell, Cutaneous/metabolism , Repressor Proteins/antagonists & inhibitors , Skin Neoplasms/enzymology , Skin Neoplasms/metabolism
5.
Br J Dermatol ; 158(4): 747-53, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18241263

ABSTRACT

BACKGROUND: The central role of Notch signalling in T-cell development and oncogenesis raises the question of the importance of this pathway in cutaneous T-cell lymphomas. OBJECTIVES: To investigate the pattern of expression of Notch and its ligands, Jagged and Delta, in skin samples of primary cutaneous CD30+ lymphoproliferative disorders. METHODS: Immunohistochemistry of formalin-fixed, paraffin-embedded skin samples from 12 patients with lymphomatoid papulosis (LyP) and 11 patients with primary cutaneous anaplastic large cell lymphoma (ALCL). Immunofluorescence studies of fresh skin samples obtained from three patients with LyP and two patients with primary cutaneous ALCL. RESULTS: We identified single Notch1-positive cells or small clusters of atypical cells in LyP. Similarly, strongly positive Jagged1 cells tended to be localized in clusters. Primary cutaneous ALCL had higher expression of Notch1 and Jagged1 compared with LyP. Cells expressing Notch1 and Jagged1 were colocalized and a subset of cells expressed both the receptor and the ligand. The expression of the ligand Delta1 was low to undetectable in both types of lymphoproliferations. A subpopulation of lymphoma cells was found to coexpress Notch1 and activated Akt kinase. CONCLUSIONS: These results imply a potential role for the Notch signalling pathway in the pathogenesis of primary cutaneous CD30+ lymphoproliferative disorders and provide a rationale for the exploration of the activity of Notch antagonists in the therapy of these diseases.


Subject(s)
Calcium-Binding Proteins/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Ki-1 Antigen/metabolism , Lymphoma, Large-Cell, Anaplastic/immunology , Lymphomatoid Papulosis/immunology , Membrane Proteins/metabolism , Receptor, Notch1/metabolism , Skin Neoplasms/immunology , Adult , Aged , Aged, 80 and over , Calcium-Binding Proteins/isolation & purification , Female , Humans , Intercellular Signaling Peptides and Proteins/isolation & purification , Jagged-1 Protein , Ki-1 Antigen/isolation & purification , Ligands , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphomatoid Papulosis/pathology , Male , Membrane Proteins/isolation & purification , Middle Aged , Receptor, Notch1/isolation & purification , Serrate-Jagged Proteins , Signal Transduction/immunology , Skin Neoplasms/pathology
6.
Leukemia ; 21(12): 2406-10, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17928883

ABSTRACT

Serglycin is the major cell-associated proteoglycan of hematopoietic cells. Previous work has demonstrated that serglycin may be involved in targeting some proteins to granules of cytotoxic lymphocytes, mast cells and neutrophils. We characterized the expression of serglycin in various hematologic malignancies by immunohistochemistry and ELISA. Serglycin expression was found to distinguish acute myeloid leukemia (AML) from acute lymphoblastic leukemia. In contrast to myeloperoxidase, serglycin was found to be a selective marker for immature myeloid cells, distinguishing AML from Philadelphia chromosome-negative chronic myeloproliferative disorders.


Subject(s)
Biomarkers, Tumor/analysis , Granulocyte Precursor Cells/chemistry , Hematologic Neoplasms/metabolism , Leukemia, Myeloid, Acute/diagnosis , Neoplasm Proteins/analysis , Proteoglycans/analysis , Vesicular Transport Proteins/analysis , Blood Cells/chemistry , Bone Marrow Cells/chemistry , Cell Differentiation , Cytoplasmic Granules/chemistry , Diagnosis, Differential , Hematologic Neoplasms/diagnosis , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/metabolism , Lymphoma, Non-Hodgkin/metabolism , Myeloproliferative Disorders/metabolism , Neoplasm Proteins/blood , Peroxidase/analysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Predictive Value of Tests , Proteoglycans/blood , Vesicular Transport Proteins/blood
7.
Leukemia ; 21(12): 2512-8, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17713545

ABSTRACT

FOXP3 is a unique marker for CD4+CD25+ regulatory T cells (Tregs). In solid tumours, high numbers of Tregs are associated with a poor prognosis. Knowledge about the implications of Tregs for the behaviour of haematological malignancies is limited. In this study, skin biopsies from 86 patients with mycosis fungoides (MF) and cutaneous T-cell lymphoma (CTCL) unspecified were analysed for the expression of FOXP3 on tumour cells and tumour-infiltrating Tregs. Labelling of above 10% of the neoplastic cells was seen in one case classified as an aggressive epidermotropic CD8+ cytotoxic CTCL. In the remaining 85 cases, the atypical neoplastic infiltrate was either FOXP3 negative (n=80) or contained only very occasional weakly positive cells (n=5). By contrast, all biopsies showed varying numbers of strongly FOXP3+ tumour-infiltrating Tregs. MF with early or infiltrated plaques had significantly higher numbers of FOXP3+ Tregs than CTCL unspecified or advanced MF with tumours or transformation to large cell lymphoma. An analysis of all patients demonstrated that increasing numbers of FOXP3+ Tregs were associated with improved survival in both MF and CTCL unspecified. In conclusion, our data indicate that the presence of FOXP3+ Tregs in CTCL is associated with disease stage and patient survival.


Subject(s)
Forkhead Transcription Factors/analysis , Lymphocytes, Tumor-Infiltrating/immunology , Lymphoma, T-Cell, Cutaneous/pathology , Mycosis Fungoides/pathology , Skin Neoplasms/pathology , T-Lymphocytes, Regulatory/immunology , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Female , Humans , Jurkat Cells/chemistry , Kaplan-Meier Estimate , Lymphocytes, Tumor-Infiltrating/chemistry , Lymphocytes, Tumor-Infiltrating/pathology , Lymphoma, T-Cell, Cutaneous/immunology , Lymphoma, T-Cell, Cutaneous/mortality , Male , Middle Aged , Mycosis Fungoides/mortality , Neoplasm Staging , Prognosis , Proportional Hazards Models , Recombinant Fusion Proteins/analysis , Skin Neoplasms/immunology , Skin Neoplasms/mortality , Survival Analysis , T-Lymphocytes, Regulatory/chemistry , T-Lymphocytes, Regulatory/pathology
8.
Br J Ophthalmol ; 90(8): 1004-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16672329

ABSTRACT

AIM: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. METHODS: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Research and Treatment of Cancer (EORTC) and the European Ophthalmic Pathology Society (EOPS). Specimens were stained with haematoxylin and eosin and an immunohistochemical panel against leucocyte antigens was applied. Diagnosis was reached by consensus of five experienced pathologists according to the World Health Organization classification system. The histopathological findings were correlated with the clinical data. RESULTS: Of 15 primary lacrimal sac lymphomas, five (33%) were diffuse large B cell lymphoma (DLBCL), five (33%) were extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), three were classified as "transitional MALT lymphoma," being in transition from MALT lymphoma to DLBCL, and two were unclassified B cell lymphomas. Nine of the patients were female, and the median age at the time of diagnosis was 71 years (range 45-95 years). The most frequent presenting symptoms were epiphora (85%), swelling in the region of the lacrimal sac (79%), and dacryocystitis (21%). All but one patient presented in stage I. Systemic spread occurred in three of nine patients (33%). The 5 year overall survival was 65%. CONCLUSIONS: DLBCL and MALT lymphoma are equally common in the lacrimal sac in contrast with the remaining periorbital and/or orbital region where MALT lymphoma predominates.


Subject(s)
Lacrimal Apparatus Diseases/diagnosis , Lymphoma, B-Cell/diagnosis , Aged , Aged, 80 and over , Antigens, CD/metabolism , Antigens, Neoplasm/metabolism , Female , Humans , Lacrimal Apparatus Diseases/pathology , Lacrimal Apparatus Diseases/therapy , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/therapy , Lymphoma, B-Cell, Marginal Zone/diagnosis , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/therapy , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/therapy , Male , Middle Aged , Retrospective Studies
9.
Eur J Ophthalmol ; 16(1): 181-5, 2006.
Article in English | MEDLINE | ID: mdl-16496268

ABSTRACT

PURPOSE: To present two cases of rapidly growing tumors in the ocular adnexa. Both tumors were Epstein-Barr virus (EBV) positive peripheral T-cell lymphoma. METHODS: Case 1 was a 60-year-old man with a non-tender ulcerating tumor involving the lateral third of both upper and lower right eyelid. Case 2 was a 55-year-old man with a swelling of the left eyelid expanding cranially and dislocating the left eye, resulting in proptosis and diplopia. Both patients underwent incisional biopsy that did not disclose the malignant nature of the tumors. Clinical evaluation resulted in suspicion of malignancy and surgical excision was performed. RESULTS: The tumors were found to be consistent with EBV-positive peripheral T-cell lymphoma. CONCLUSIONS: Peripheral T-cell lymphoma is uncommon but a diagnosis to be considered in a patient with a tumorous lesion in the eye region. Furthermore, peripheral T-cell lymphoma may be EBV-positive.


Subject(s)
Epstein-Barr Virus Infections/virology , Eyelid Neoplasms/virology , Herpesvirus 4, Human/isolation & purification , Lymphoma, T-Cell/pathology , Lymphoma, T-Cell/virology , Antigens, Viral/analysis , Biomarkers, Tumor/analysis , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Infections/surgery , Eyelid Neoplasms/pathology , Eyelid Neoplasms/surgery , Herpesvirus 4, Human/chemistry , Humans , Lymphoma, T-Cell/surgery , Male , Middle Aged , Tomography, X-Ray Computed
10.
Histopathology ; 41(1): 1-29, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12121233

ABSTRACT

Neoplasms of histiocytes and dendritic cells are rare, and their phenotypic and biological definition is incomplete. Seeking to identify antigens detectable in paraffin-embedded sections that might allow a more complete, rational immunophenotypic classification of histiocytic/dendritic cell neoplasms, the International Lymphoma Study Group (ILSG) stained 61 tumours of suspected histiocytic/dendritic cell type with a panel of 15 antibodies including those reactive with histiocytes (CD68, lysozyme (LYS)), Langerhans cells (CD1a), follicular dendritic cells (FDC: CD21, CD35) and S100 protein. This analysis revealed that 57 cases (93%) fit into four major immunophenotypic groups (one histiocytic and three dendritic cell types) utilizing six markers: CD68, LYS, CD1a, S100, CD21, and CD35. The four (7%) unclassified cases were further classifiable into the above four groups using additional morphological and ultrastructural features. The four groups then included: (i) histiocytic sarcoma (n=18) with the following phenotype: CD68 (100%), LYS (94%), CD1a (0%), S100 (33%), CD21/35 (0%). The median age was 46 years. Presentation was predominantly extranodal (72%) with high mortality (58% dead of disease (DOD)). Three had systemic involvement consistent with 'malignant histiocytosis'; (ii) Langerhans cell tumour (LCT) (n=26) which expressed: CD68 (96%), LYS (42%), CD1a (100%), S100 (100%), CD21/35 (0%). There were two morphological variants: cytologically typical (n=17) designated LCT; and cytologically malignant (n=9) designated Langerhans cell sarcoma (LCS). The LCS were often not easily recognized morphologically as LC-derived, but were diagnosed based on CD1a staining. LCT and LCS differed in median age (33 versus 41 years), male:female ratio (3.7:1 versus 1:2), and death rate (31% versus 50% DOD). Four LCT patients had systemic involvement typical of Letterer-Siwe disease; (iii) follicular dendritic cell tumour/sarcoma (FDCT) (n=13) which expressed: CD68 (54%), LYS (8%), CD1a (0%), S100 (16%), FDC markers CD21/35 (100%), EMA (40%). These patients were adults (median age 65 years) with predominantly localized nodal disease (75%) and low mortality (9% DOD); (iv) interdigitating dendritic cell tumour/sarcoma (IDCT) (n=4) which expressed: CD68 (50%), LYS (25%), CD1a (0%), S100 (100%), CD21/35 (0%). The patients were adults (median 71 years) with localized nodal disease (75%) without mortality (0% DOD). In conclusion, definitive immunophenotypic classification of histiocytic and accessory cell neoplasms into four categories was possible in 93% of the cases using six antigens detected in paraffin-embedded sections. Exceptional cases (7%) were resolvable when added morphological and ultrastructural features were considered. We propose a classification combining immunophenotype and morphology with five categories, including Langerhans cell sarcoma. This simplified scheme is practical for everyday diagnostic use and should provide a framework for additional investigation of these unusual neoplasms.


Subject(s)
Biomarkers, Tumor , Dendritic Cells/immunology , Histiocytes/immunology , Histiocytic Disorders, Malignant/classification , Lymphoma/classification , Adult , Aged , Biomarkers, Tumor/immunology , Dendritic Cells/classification , Female , Histiocytes/classification , Histiocytes/ultrastructure , Histiocytic Disorders, Malignant/diagnosis , Histiocytic Disorders, Malignant/immunology , Humans , Immunohistochemistry , Immunophenotyping , Lymphoma/diagnosis , Lymphoma/immunology , Lymphoma/ultrastructure , Male , Microscopy, Electron , Middle Aged
11.
Br J Dermatol ; 146(1): 148-53, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11841384

ABSTRACT

The clinical, histological, phenotypic and genotypic features of a lymphoblastoid natural killer (NK)-cell lymphoma presenting in the skin in a young caucasian woman are described. The disease behaved aggressively, but long-lasting remission was obtained by combination chemotherapy followed by autologous bone marrow transplantation. The blastoid cells were positive for terminal deoxynucleotidyl transferase, CD34, CD56 and CD4. Furthermore, the NK-cell receptor complex CD94/NKG2 was strongly expressed, as shown by examination with reverse transcription-polymerase chain reaction. The T-cell receptor (TCR)-gamma genes were in germline, and with the exception of CD4 all T-cell antigens were negative, including CD3, TCR-beta, TCR-delta, TIA-1, granzyme B and perforin. Epstein-Barr virus was negative, and no expression was seen of myeloid cell-associated markers. Molecular analysis showed no abnormalities of the CDKN2A (p16), CDKN2B (p15) or TNFRSF6 (Fas) genes. By contrast, a 34-bp deletion in exon 7 of the TP53 (p53) gene was detected. It is suggested that lymphoblastoid NK-cell lymphoma, which is a rare but distinctive disease, originates from NK cell precursors and may be associated with and possibly caused by alterations in the TP53 gene. Experience is too limited to warrant therapeutic suggestions. However, stem cell transplantation may be a useful option in younger patients.


Subject(s)
Antigens, CD/genetics , Gene Deletion , Killer Cells, Natural , Lectins, C-Type , Membrane Glycoproteins/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Skin Neoplasms/genetics , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/administration & dosage , Bone Marrow Transplantation , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , NK Cell Lectin-Like Receptor Subfamily D , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Treatment Outcome , Vincristine/administration & dosage
12.
J Invest Dermatol ; 116(3): 353-8, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11231307

ABSTRACT

In this study we have used in situ hybridization with radiolabeled antisense RNA probes to examine the expression of mRNA for urokinase-type plasminogen activator and its receptor in histologic samples of squamous cell (n = 7) and basal cell (n = 7) carcinomas of the skin. Messenger RNA for both urokinase-type plasminogen activator and its receptor were expressed in all of the squamous cell carcinomas, but could not be detected in the basal cell carcinomas. In all of the seven squamous cell carcinomas a signal for urokinase-type plasminogen activator receptor mRNA was detected focally in well-differentiated cancer cells surrounding keratinized pearls, and in four specimens urokinase-type plasminogen activator receptor mRNA was in addition expressed by cancer cells at the edge of invasively growing strands of tumor. Urokinase-type plasminogen activator mRNA expression was found in virtually all the cancer cells of the squamous cell carcinomas, and importantly we found, by hybridizations for urokinase-type plasminogen activator and its receptor mRNA on adjacent sections of squamous cell carcinomas, that it was exactly the invading cancer cells that simultaneously expressed both these components required for plasmin-mediated proteolysis at the cell surface. We have previously shown that both urokinase-type plasminogen activator and its receptor mRNA are expressed by the leading-edge keratinocytes in regenerating epidermis during mouse skin wound healing, and that wound healing is impaired in mice made deficient in plasminogen by targeted gene disruption. We propose that there are similarities between the mechanisms of generation and regulation of extracellular proteolysis during skin re-epithelialization and squamous cell carcinoma invasion. The ability of the squamous carcinoma cells to mimic the "invasive" phenotype of re-epithelializing keratinocytes may be one of the factors that make squamous cell carcinomas more aggressive tumors than basal cell carcinomas.


Subject(s)
Carcinoma, Squamous Cell/metabolism , RNA, Messenger/metabolism , Skin Neoplasms/metabolism , Urokinase-Type Plasminogen Activator/genetics , Carcinoma, Basal Cell/metabolism , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Humans , Neoplasm Invasiveness , Receptors, Cell Surface/genetics , Receptors, Urokinase Plasminogen Activator , Skin Neoplasms/pathology
13.
Leukemia ; 14(10): 1727-35, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11021747

ABSTRACT

The INK4a/ARF locus at chromosome 9p21 encodes two structurally and functionally distinct molecules with tumor-suppressive properties. p16INK4a controls cell cycle progression by inhibiting phosphorylation of the retinoblastoma protein (Rb), while ARF prevents MDM2-mediated degradation of p53. By using a panel of PCR-based methods, we have examined the status of the p16INK4a, ARF and p53 genes in 123 cases of non-Hodgkin's lymphoma (NHL) at diagnosis. Alterations of one or more of these genes were detected in seven of 36 (19%) cases with low- to intermediate-grade histology, and in 35 of 87 (40%) cases with aggressive histology. For the aggressive lymphomas, the Kaplan-Meier estimate of overall survival for cases with disruption of either p16INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5 year survival 45% vs 35%; P= 0.85), suggesting that selective inactivation of one of the pathways does not significantly influence overall survival. By contrast, the 5-year survival was only 7% for cases with concurrent disruption of p16INK4a and the ARF-p53 pathway vs 38% for cases with retention of one or both pathways (P = 0.005). Similar results were obtained when the analysis was confined to diffuse large B cell lymphomas (P= 0.019). On stepwise multivariate regression analysis including factors from the international prognostic index, concurrent disruption of p16INK4a and the ARF-p53 pathway was an independent negative prognostic factor in NHL with aggressive histology (P = 0.006). Our results suggest that the compound status of the p16INK4a and ARF-p53 pathways is a major determinant of outcome in NHL.


Subject(s)
ADP-Ribosylation Factors/genetics , Genes, p16 , Genes, p53 , Lymphoma, Non-Hodgkin/genetics , DNA Methylation , Gene Deletion , Humans , Lymphoma, Non-Hodgkin/pathology , Mutation , Prognosis , Promoter Regions, Genetic , Survival Analysis
14.
Ann Hematol ; 79(3): 158-60, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10803939

ABSTRACT

Pathological or spontaneous rupture of the spleen has been described in a variety of diseases affecting the spleen, with infections being cited as the cause in most cases. In hematological malignancies it is a rare event, despite the frequent involvement of the spleen in these diseases. It has, however, been described in patients with acute and chronic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma of B-cell origin, mycosis fungoides, and so-called histiocytic lymphoma. Here, we present a fatal case of splenic rupture caused by infiltration of a peripheral T-cell lymphoma, unspecified according to the REAL classification. The importance of a correct diagnosis and fast surgery is emphasized.


Subject(s)
Lymphoma, T-Cell/pathology , Splenic Rupture/etiology , Fatal Outcome , Humans , Male , Middle Aged , Neoplasm Invasiveness , Spleen/pathology
15.
Br J Dermatol ; 142(5): 913-23, 2000 May.
Article in English | MEDLINE | ID: mdl-10809848

ABSTRACT

The clinical, histological, phenotypic and genotypic features of 21 primary cutaneous B-cell lymphomas (CBCLs) have been investigated. The patients were 13 men and eight women aged 34-91 years (median 67) at diagnosis. Eighteen patients had localized disease, and three had multiple skin lesions at diagnosis. Twelve patients developed cutaneous or extracutaneous recurrences, and five died from malignant lymphoma 7-84 months (median 36) after diagnosis. Histological examination showed features of marginal zone/mucosa-associated lymphoid tissue (MALT)-type lymphoma in 12 cases. Three of these had transformed to diffuse large B-cell lymphoma (DLBCL) in relapse biopsies. The remaining cases were seven primary DLBCLs and two cases tentatively classified as follicle centre cell (FCC) lymphoma. The neoplastic B cells showed similar phenotypes and genotypes in most cases (CD20+, CD79+, CD5-, CD10-, cyclin D1-, bcl-2+, bcl-x-, bax-, t(14;18)-negative). p53 protein was expressed in five cases, and four harboured mis-sense or loss-of-function mutations in the p53 gene. Deletion or promoter region hypermethylation of the p16INK4a gene was detected in two patients with DLBCL. The level of retinoblastoma protein expression and the proliferative fraction were significantly higher in DLBCL (> 50%) than in MALT- or FCC-type lymphomas (< 10%). Features associated with an unfavourable prognosis were the presence of multiple skin lesions at diagnosis, transformation from MALT-type lymphoma to DLBCL, and possibly p16INK4a aberrations. It is concluded that most CBCLs are dissimilar from FCC lymphomas and seem to be more closely related to marginal zone/MALT-type lymphomas. It is also suggested that there are fundamental differences between DLBCL and other histological categories of CBCL, indicating that cutaneous DLBCL is a separate entity with an increased growth potential and genetic features similar to DLBCL originating in other anatomical sites.


Subject(s)
Lymphoma, B-Cell/pathology , Skin Neoplasms/pathology , Adult , Aged , Aged, 80 and over , DNA Methylation , Female , Gene Deletion , Gene Expression , Genes, bcl-2 , Genes, p16 , Genes, p53 , Genotype , Humans , Immunophenotyping , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Middle Aged , Mutation, Missense , Neoplasm Recurrence, Local/pathology , Phenotype , Prognosis , Promoter Regions, Genetic , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Skin Neoplasms/genetics , bcl-2-Associated X Protein
17.
APMIS ; 107(7): 636-44, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10440059

ABSTRACT

During recent years it has become increasingly evident that L&H cells in nodular lymphocytic predominance (LP) Hodgkin's disease (HD) and Hodgkin and Reed-Sternberg (H-RS) cells in approximately half the cases of classical HD originate from B-lymphocytes, and that H-RS cells in most of the remaining cases of classical HD express a null phenotype. The pathogenesis of HD is unknown. An association with Epstein-Barr virus (EBV) has been suggested and there are also indications that genes involved in programmed cell death (apoptosis) may be implicated. In this study, the expression of four apoptosis-related proteins (bcl-2, bcl-x, bax and p53) in 53 cases of HD was examined and the data were correlated with the genotype, the EBV status and the phenotype (B, T or null) of the neoplastic cells. The H-RS cells expressed a B-cell phenotype in 3/3 cases of nodular LP and in 19/ 50 (38%) cases of classical HD. The remaining cases showed a null-cell phenotype in 29/50 (58%) and a T-cell phenotype in 2/50 (4%). EBV was more often positive in B (14/19, 74%) than in null (7/29, 24%) type HD. The H-RS cells were bcl-2-positive in 19/53 (36%), bcl-x-positive in 17/53 (32%), bax-positive in 1/53, and p53-positive in 41/53 (77%) cases. No relationship was found between bcl-2 expression and EBV status, or between bcl-2 and bcl-x expression. A t(14;18) translocation was seen in 2 of 34 cases. P53 point mutations were not detected. Our findings indicate that nodular LP and classical HD originate from B-cells in a high proportion of cases. They also suggest a role for bcl-2, bcl-x and p53 in tumorigenesis. The pathogenesis is not known at this stage.


Subject(s)
Apoptosis/genetics , Hodgkin Disease/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins/genetics , Tumor Suppressor Protein p53/genetics , Animals , Antigens, CD/biosynthesis , Base Sequence , Herpesvirus 4, Human/genetics , Hodgkin Disease/pathology , Humans , Molecular Sequence Data , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , RNA, Viral/genetics , Rabbits , Tumor Suppressor Protein p53/biosynthesis , Viral Matrix Proteins/biosynthesis , bcl-2-Associated X Protein , bcl-X Protein
18.
Blood ; 92(9): 3018-24, 1998 Nov 01.
Article in English | MEDLINE | ID: mdl-9787134

ABSTRACT

Fas (APO-1/CD95) is a cell-surface receptor involved in cell death signaling. Germline mutations in the Fas gene have been associated with autoimmune lymphoproliferative syndrome, and somatic Fas mutations have been found in multiple myeloma. We have examined the entire coding region and all splice sites of the Fas gene in 150 cases of non-Hodgkin's lymphoma. Overall, mutations were identified in 16 of the tumors (11%). Missense mutations within the death domain of the receptor were associated with retention of the wild-type allele, indicating a dominant-negative mechanism, whereas missense mutations outside the death domain were associated with allelic loss. Fas mutations were identified in 3 (60%) MALT-type lymphomas, 9 (21%) diffuse large B-cell lymphomas, 2 (6%) follicle center cell lymphomas, 1 (50%) anaplastic large cell lymphoma, and 1 unusual case of B-cell chronic lymphocytic leukemia with a marked tropism for skin. Among the 16 patients with somatic Fas mutations, 15 showed extranodal disease at presentation, and 6 relapsed in extranodal areas. Ten of 13 evaluable patients showed features suggestive of autoreactive disease. Our data indicate that somatic disruption of Fas may play a role in the pathogenesis of some lymphomas, and suggest a link between Fas mutation, cancer and autoimmunity.


Subject(s)
Autoimmunity/genetics , DNA, Neoplasm/genetics , Lymphoma, Non-Hodgkin/genetics , Neoplasm Proteins/genetics , fas Receptor/genetics , Adult , Aged , Aged, 80 and over , Alleles , Amino Acid Substitution , Apoptosis , Autoimmune Diseases/complications , Autoimmune Diseases/genetics , Codon/genetics , DNA Mutational Analysis , Female , Genetic Predisposition to Disease , Humans , Lymphoma, Non-Hodgkin/classification , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Mutation, Missense , Neoplasm Proteins/physiology , Paraneoplastic Syndromes/etiology , Paraneoplastic Syndromes/immunology , Paraneoplastic Syndromes/pathology , Polymorphism, Genetic , Protein Structure, Tertiary , RNA Splicing/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sjogren's Syndrome/complications , Sjogren's Syndrome/genetics , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/genetics , fas Receptor/physiology
19.
Leukemia ; 12(8): 1266-71, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9697882

ABSTRACT

Mantle cell lymphomas (MCL) are morphologically and immunophenotypically distinctive lymphoid neoplasms characterised by overexpression of cyclin D1. Recent studies have suggested that co-operating aberrations of cell cycle associated genes may provide a growth advantage to a tumour. To address this issue further, we investigated five typical and three aggressive (blastoid) MCL for alterations in the cell cycle regulating genes p15, p16, CDK4, Rb and p53. In 3/3 aggressive cases with cyclin D1 overexpression we found aberration of at least one additional gene. One case showed diminished expression of the retinoblastoma protein (pRb); one case harboured deletion of both p15 and p16; and one case exhibited both deletion of p16 and point mutation of p53. However, we also identified two typical cases which in addition to cyclin D1 overexpression exhibited diminished pRb expression and p15 and p16 hypermethylation, respectively. Our findings confirm and extend other recent investigations and indicate that co-operating genetic alterations of cell cycle-associated genes may contribute to the pathogenesis of MCL.


Subject(s)
Cell Cycle Proteins , Genes, cdc , Lymphoma, Non-Hodgkin/genetics , Proto-Oncogene Proteins , Tumor Suppressor Proteins , Adult , Aged , Aged, 80 and over , Cyclin D1/metabolism , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinase Inhibitor p15 , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Cyclin-Dependent Kinases/metabolism , Female , Genotype , Humans , Male , Middle Aged , Phenotype , Retinoblastoma Protein/metabolism , Transcription Factors/metabolism , Tumor Suppressor Protein p53/metabolism
20.
J Intern Med ; 244(1): 71-8, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9698027

ABSTRACT

OBJECTIVES: To analyse the clinical course and the histopathology of primary gastrointestinal non-Hodgkin's lymphoma (GI-NHL) in adult patients and to investigate a possible impact of Helicobacter pylori. DESIGN/SETTING: Retrospective study of all adult patients in Copenhagen county diagnosed during a 6-year period with NHL. SUBJECTS: A total of 55 patients with GI-NHL diagnosed during the period from 1985 to the end of 1990. RESULTS: Twenty-eight patients had primary lymphoma in the stomach, 14 in the small intestine, 11 in the large intestine and two patients had multifocal involvement. The dominant presenting symptoms were abdominal pain, weight loss, diarrhoea, constipation and fatigue. Acute emergency problems such as severe haemorrhage or perforation at initial presentation were unusual. According to the revised European-American lymphoma (REAL) classification, diffuse large B-cell lymphoma was the most frequent histologic subtype comprising 53% of the cases. Helicobacter pylori infection was documented in 15 of 25 evaluable patients (60%) with gastric lymphomas and was not associated with any specific histological subtype. Endoscopic procedures and barium X-rays were the diagnostic approaches with highest sensitivity. In total, 30 patients (58%) achieved complete remission, 10 (19%) achieved partial remission, and 12 (23%) did not respond to treatment. The overall 5 year survival rate was 0.36 without statistically significant difference between the histological subtypes. Likewise the presence of Helicobacter pylori did not affect survival. CONCLUSION: Primary GI-NHL is a heterogeneous disease entity with considerable therapeutic controversies. No specific clinical or histological phenotype was associated with the presence of Helicobacter pylori.


Subject(s)
Gastrointestinal Neoplasms/pathology , Lymphoma, Non-Hodgkin/pathology , Adult , Age Distribution , Aged , Aged, 80 and over , Combined Modality Therapy , Denmark , Female , Gastrointestinal Neoplasms/complications , Gastrointestinal Neoplasms/mortality , Gastrointestinal Neoplasms/therapy , Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Humans , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Population Surveillance/methods , Registries , Retrospective Studies , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...